The next generation
of drug discovery
is female.

Nexagen is an AI-powered drug discovery platform built specifically for women's health, starting with the conditions science has ignored the longest.

Fill Out Our Questionnaire

Early access · Built by women, for women

Target Identification Sex-Aware Analysis Compound Repurposing Literature Synthesis Endometriosis Research Biomarker Discovery Women's Health AI Drug Discovery Target Identification Sex-Aware Analysis Compound Repurposing Literature Synthesis Endometriosis Research Biomarker Discovery Women's Health AI Drug Discovery

The Problem

Drug discovery for endometriosis has a problem.

Decades of research have been built on male cell lines, male animal models, and clinical trials that excluded women. The result: conditions affecting millions of women have almost no approved treatments.

Nexagen changes that. We read everything and we find the connections researchers don't have time to find themselves.

176M
women affected by endometriosis worldwide
9 yrs
average delay to diagnosis
0
approved disease-modifying treatments for endometriosis
£8.2B
annual economic burden of women's health conditions in the UK

The Platform

From literature to lead compounds faster.

Nexagen's AI synthesises across fragmented disciplines: immunology, gynaecology and genomics to produce insights no single researcher could find alone.

01
Sex-Aware Literature Synthesis
Searches thousands of papers across disciplines. Prioritises female-derived research. Finds cross-disciplinary connections no one has.
02
Target Identification
Highlights novel, biologically plausible drug targets for endometriosis. Prioritised by druggability and evidence strength.
03
Compound Repurposing
Maps existing approved drugs against identified targets. The fastest path to treatment. Shortens timelines compared to de novo drug discovery.

The Team

Built by the people closest to the problem.

TD
Toni Disu
Co-Founder · CEO
BSc Medical Innovation & Enterprise · MRes Medical Device Design and Entrepreneurship, Imperial College London. Background in medical devices, biomedical AI, and venture.
TB
Tanvi Bhatla
Co-Founder · COO
BSc Neuroscience · MRes Neurotechnology, Imperial College London. Expertise in neurobiological systems, neural interfaces, and computational methods applied to medical research.
SH
Sophia Hussain
Co-Founder · CTO
BSc Mathematics with Actuarial Science. Quantitative background applied to biological data; modelling, analysis, and the statistical foundations of drug discovery research.

Selected for HackNation Venture Lab Cohort 2. 30 teams from 5,500+ applicants. Backed by EWOR and Databricks.

Be first to access Nexagen.

We're onboarding a small group of research teams and biotech founders to shape the platform. If you work in women's health drug discovery, we want to hear from you.

Fill Out Our Questionnaire